Clinical Trial Update: First-in-man Trial to Assess the Safety, Performance and Clinical Benefit of the TRICENTO G2 Transcatheter Valve System for Tricuspid Regurgitation [NA]

View source ↗

Summary

This is a first-in-man trial evaluating the TRICENTO G2 Transcatheter Valve System for symptomatic tricuspid regurgitation. The study status is NOT_YET_RECRUITI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tricuspid Regurgitation

Drugs mentioned

• TRICENTO G2 Transcatheter Valve System

Snippet

Sponsor: Medira GmbH | Conditions: Symptomatic Tricuspid Regurgitation (TR) Graded as Severe or Greater | NA | Status: NOT_YET_RECRUITING